A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer
Luís Manso(Research Institute Hospital 12 de Octubre), Miguel Quintela-Fandiño(Spanish National Cancer Research Centre), José Á. García-Sáenz(Hospital Clínico San Carlos), Lucía González Cortijo(Hospital Universitario Quirónsalud Madrid), Silvana Mourón(Spanish National Cancer Research Centre), Rodrigo Sánchez-Bayona(Research Institute Hospital 12 de Octubre), Leonardo D. Garma(Spanish National Cancer Research Centre), María J. Bueno(Spanish National Cancer Research Centre), Alfonso Cortés(Hospital Universitario Ramón y Cajal), Serafín Morales(Hospital Universitari Arnau de Vilanova), Juan Antonio Guerra(Hospital Universitario de Fuenlabrada), Juan Miguel Cejalvo(Universitat de València)
Cited by 2
Related Papers
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
|The Lancet Oncology|2017|340
Circulating Tumor Cells in Breast Cancer Patients Treated by Neoadjuvant Chemotherapy: A Meta-analysis
|JNCI Journal of the National Cancer Institute|2018|282
The clinical use of circulating tumor cells (CTCs) enumeration for staging of metastatic breast cancer (MBC): International expert consensus paper
|Critical Reviews in Oncology/Hematology|2018|268